Published in Cancer Weekly, August 28th, 1995
Biotechnological advances have produced the ability to derive specific recognition domains from monoclonal antibodies (mAb). By recombining variable regions of light and heavy chains, and integrating them into single polypeptides, researchers can use single-chain antibody (Ab) derivatives for specific targeting purposes.
Winfried Wels et al. have developed a fusion protein which is capable of recognizing the ErbB-2 receptor which is overproduced in many adenocarcinomas of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.